SG10201608307WA - Cd3 binding polypeptides - Google Patents

Cd3 binding polypeptides

Info

Publication number
SG10201608307WA
SG10201608307WA SG10201608307WA SG10201608307WA SG10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA SG 10201608307W A SG10201608307W A SG 10201608307WA
Authority
SG
Singapore
Prior art keywords
binding polypeptides
polypeptides
binding
Prior art date
Application number
SG10201608307WA
Inventor
Philip Huat Tan
Sateesh Kumar Natarajan
Catherine J Mcmahan
Original Assignee
Emergent Product Dev Seattle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Seattle filed Critical Emergent Product Dev Seattle
Publication of SG10201608307WA publication Critical patent/SG10201608307WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201608307WA 2012-04-20 2013-04-18 Cd3 binding polypeptides SG10201608307WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201608307WA true SG10201608307WA (en) 2016-11-29

Family

ID=49384230

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608307WA SG10201608307WA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201406346SA SG11201406346SA (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Country Status (16)

Country Link
US (1) US10202452B2 (en)
EP (1) EP2839019A4 (en)
JP (2) JP6509724B2 (en)
KR (1) KR20150004856A (en)
CN (1) CN104487587A (en)
AU (2) AU2013249267A1 (en)
BR (1) BR112014025830A8 (en)
CA (1) CA2870545A1 (en)
HK (2) HK1207398A1 (en)
IL (1) IL235093B (en)
IN (1) IN2014MN02293A (en)
MX (1) MX366813B (en)
RU (1) RU2673153C2 (en)
SG (2) SG10201608307WA (en)
UA (1) UA119227C2 (en)
WO (1) WO2013158856A2 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
JP2014518615A (en) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー Prostate-specific membrane antigen binding proteins and related compositions and methods
AU2013249267A1 (en) 2012-04-20 2014-10-23 Aptevo Research And Development Llc CD3 binding polypeptides
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2937866A1 (en) 2014-01-24 2015-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antibodies against f glycoprotein of hendra and nipah viruses
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CN107108738A (en) 2014-07-25 2017-08-29 西托姆克斯治疗公司 Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
PT3247725T (en) 2015-01-23 2020-10-07 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
SG10201912666PA (en) 2015-04-13 2020-02-27 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
PE20221262A1 (en) 2015-04-13 2022-08-16 Pfizer THERAPEUTIC ANTIBODIES AND THEIR USES
WO2016178996A1 (en) * 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN104892765B (en) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 A kind of bispecific antibody of AntiCD3 McAb antigen and Her 2 antigen
JOP20160154B1 (en) * 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
EP3352760A4 (en) * 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
CN108026179A (en) * 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 With reference to mesothelin and the bispecific T cell activation antigen binding molecules of CD3
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
MX2018010988A (en) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy.
CN107365387B (en) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 Bispecific antigen binding construct, preparation method and application thereof
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112018073761A2 (en) * 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. single chain variable fragment cd3 binding proteins
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN110603266A (en) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 Type II anti-CD 20 and anti-CD 20/CD3 bispecific antibodies for the treatment of cancer
CN106117358A (en) * 2016-06-16 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084047A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106117361A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084049A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106146661A (en) * 2016-06-17 2016-11-23 中山大学 AntiCD3 McAb single domain antibody
CN106117359A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084048A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
CN106117360A (en) * 2016-06-17 2016-11-16 中山大学 AntiCD3 McAb single domain antibody
CN106084046A (en) * 2016-06-17 2016-11-09 中山大学 AntiCD3 McAb single domain antibody
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
CN106146662A (en) * 2016-07-18 2016-11-23 中山大学 AntiCD3 McAb single domain antibody
CR20220408A (en) * 2016-09-14 2022-10-20 Teneobio Inc Cd3 binding antibodies
CN109952112B (en) * 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 CD123 binding proteins and related compositions and methods
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110325209A (en) 2017-02-24 2019-10-11 宏观基因有限公司 CD137 and the bi-specific binding molecule of tumour antigen and application thereof can be combined
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN110945026B (en) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 Heavy chain-only anti-BCMA antibodies
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
CN111201242A (en) * 2017-06-22 2020-05-26 财团法人生物技术开发中心 Asymmetric heterodimeric FC-SCFV fusion anti-GLOBO H and anti-CD 3 bispecific antibodies and uses thereof in cancer therapy
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. Anti-cd3 antibodies and methods of making and using thereof
JP7066837B2 (en) 2017-10-13 2022-05-13 ハープーン セラピューティクス,インク. B cell maturation antigen binding protein
PT3694529T (en) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Trispecific proteins and methods of use
TW202428622A (en) 2017-10-18 2024-07-16 瑞士商諾華公司 Compositions and methods for selective protein degradation
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
JOP20200157A1 (en) 2017-12-22 2022-10-30 Teneobio Inc Heavy chain antibodies binding to cd22
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
CN112533950B (en) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 anti-CD 3e antibodies and uses thereof
MA53094A (en) 2018-07-02 2021-05-12 Amgen Inc ANTI-STEAP1 ANTIGEN BINDING PROTEIN
BR112021003305A2 (en) 2018-08-31 2021-05-25 Novartis Ag methods for producing cells that express chimeric antigen receptor
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3110706A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN116396386A (en) * 2018-12-07 2023-07-07 江苏恒瑞医药股份有限公司 CD3 antibodies and pharmaceutical uses thereof
CN116178547A (en) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 CD3 antigen binding fragments and uses thereof
TW202045207A (en) 2019-02-25 2020-12-16 瑞士商諾華公司 Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CN113005088B (en) * 2019-12-19 2024-06-04 苏州方德门达新药开发有限公司 Engineered T cells, their preparation and use
MX2022008655A (en) 2020-01-13 2022-09-23 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components.
IL294458A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Formulations for protein therapeutics
BR112022016550A2 (en) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc FLT3-BINDING PROTEINS AND METHODS OF USE
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
IL298046A (en) 2020-05-11 2023-01-01 Janssen Biotech Inc Methods for treating multiple myeloma
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
IL301956A (en) * 2020-10-07 2023-06-01 Dren Bio Inc Anti-dectin-1 antibodies and methods of use thereof
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN118056008A (en) 2021-04-27 2024-05-17 诺华股份有限公司 Virus vector production system
US20240209116A1 (en) * 2021-04-28 2024-06-27 Ngm Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
JP2024509664A (en) 2021-04-30 2024-03-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Medication for treatment with anti-CD20/anti-CD3 bispecific antibodies
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
JP2024519964A (en) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー Dosing regimens for protein therapeutics
JP2024531364A (en) 2021-08-20 2024-08-29 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202404637A (en) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
CN115029318B (en) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 Mesenchymal stem cell carrying multi-specific antibody gene and pharmaceutical application thereof
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
PT737207E (en) 1994-01-11 2005-02-28 Dyax Corp HUMAN PLASMA INHIBITORS DERIVED FROM KUNITZ DOMAINS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE69731836T2 (en) 1996-07-23 2005-12-01 Pangenetics B.V. INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
DE69922159T2 (en) 1998-01-23 2005-12-01 Vlaams Interuniversitair Instituut Voor Biotechnologie MULTI-PURPOSE ANTIBODY DERIVATIVES
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU2002226930A1 (en) * 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (en) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Medicinal preparation to prevent transplant detachment, monoclonal antibody to cd3 antigen of human t-lymphocytes, hybridome and method to treat patients suffering acute transplant detachment reaction following kidney transplantation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CA2555503C (en) 2004-02-16 2018-03-27 Micromet Ag Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AR056142A1 (en) 2005-10-21 2007-09-19 Amgen Inc METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY
WO2007114319A1 (en) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
WO2007145941A2 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
US20100015142A1 (en) 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
AU2008287195A1 (en) 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102203258A (en) 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-b antagonist multi-target binding proteins
CA2729749A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tnf-a antagonist multi-target binding proteins
KR20110043643A (en) 2008-07-02 2011-04-27 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Il6 immunotherapeutics
CA2732574A1 (en) 2008-07-28 2010-02-04 Philip Tan Multi-specific binding proteins targeting b cell disorders
CN102164960A (en) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 Bispecific anti-EGFR/anti-IGF-1R antibodies
EP2344540B1 (en) 2008-10-02 2017-11-29 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20110217302A1 (en) * 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
ME02505B (en) * 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimer binding proteins and uses thereof
JP2014518615A (en) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル, エルエルシー Prostate-specific membrane antigen binding proteins and related compositions and methods
KR101308922B1 (en) * 2012-02-15 2013-09-23 주식회사 경동나비엔 Dual venturi for burner
AU2013249267A1 (en) 2012-04-20 2014-10-23 Aptevo Research And Development Llc CD3 binding polypeptides

Also Published As

Publication number Publication date
RU2014142166A (en) 2016-06-10
AU2017228643A1 (en) 2017-10-05
JP2018138039A (en) 2018-09-06
EP2839019A4 (en) 2016-03-30
BR112014025830A8 (en) 2017-10-10
KR20150004856A (en) 2015-01-13
WO2013158856A2 (en) 2013-10-24
HK1207398A1 (en) 2016-01-29
HK1208707A1 (en) 2016-03-11
CA2870545A1 (en) 2013-10-24
IL235093A0 (en) 2014-12-31
IN2014MN02293A (en) 2015-08-07
US20150232557A1 (en) 2015-08-20
MX2014012578A (en) 2015-05-11
IL235093B (en) 2019-09-26
EP2839019A2 (en) 2015-02-25
CN104487587A (en) 2015-04-01
UA119227C2 (en) 2019-05-27
RU2673153C2 (en) 2018-11-22
AU2017228643B2 (en) 2019-12-05
SG11201406346SA (en) 2014-11-27
AU2013249267A1 (en) 2014-10-23
JP2015521032A (en) 2015-07-27
JP6509724B2 (en) 2019-05-08
BR112014025830A2 (en) 2017-06-20
MX366813B (en) 2019-07-25
US10202452B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
HK1208707A1 (en) Cd3 binding polypeptides cd3
HUS2400016I1 (en) Anti-fcrn antibodies
IL291571A (en) Cx3cr1-binding polypeptides
HK1210964A1 (en) Immunotherapy with binding agents
HK1212711A1 (en) Bcma antigen binding proteins bcma
HK1204571A1 (en) Protease-regulated antibodies
IL233793B (en) Mica binding agents
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
AP2015008266A0 (en) 1L-18 binding molecules
HK1207656A1 (en) Albumin binding polypeptide
GB201220474D0 (en) Polypeptides
HK1210793A1 (en) Abd binding polypeptide
PL2928935T3 (en) Binders
PL2928936T3 (en) Binder
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HK1207657A1 (en) Her3 binding polypeptides her3
EP2868485A4 (en) Binder
EP2793918A4 (en) Hdc-sign binding peptides
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201200563D0 (en) Binding molecule
GB201203944D0 (en) Binding polypeptides
GB201103961D0 (en) Binding polypeptides
GB201214293D0 (en) Binding surfaces
PL2641462T3 (en) Binding device
GB201211503D0 (en) Heparin binding peptides